ACEL - Awarded U.S. Patent - NEWS
ALFACELL Awarded U.S. Patent for ONCONASE Variants
Intellectual Property Portfolio Broadened
BLOOMFIELD, N.J.--(BUSINESS WIRE)--March 31, 1998-- ALFACELL Corporation (NASDAQ: ACEL - news) announced today that it has been awarded
United States Patent No. 5,728,805 which covers a family of variants of ONCONASE(R), the Company's flagship product. A patent covering the amino acid
sequence of ONCONASE was issued in 1996 providing patent protection until the year 2013. The Company also owns other U.S. and foreign patents which cover
ONCONASE, process technology for making ONCONASE and combinations of ONCONASE with certain other pharmaceuticals.
''The importance of this patent is that it broadens the patent protection of ALFACELL's technology platform by encompassing not only our flagship product,
ONCONASE, but also other ribonucleases closely related to ONCONASE,'' stated Kuslima Shogen, CEO and Chairman of the Board of ALFACELL.
ALFACELL Corporation is a leader in the development of ribonucleases (RNases) for therapeutic applications. ONCONASE, an antitumor agent, is currently
being investigated in Phase III clinical trials in patients with advanced pancreatic adenocarcinoma and malignant mesothelioma. ALFACELL is located in Bloomfield,
New Jersey. The Company's common stock is traded on NASDAQ under the symbol ''ACEL''.
Contact:
Gail E. Fraser
Chief Financial Officer
(973) 748-8082 |
